AKT1 and melanoma: Activating mutations in the PI3K/Akt pathway have also been observed–albeit at a lower incidence (2–9%)–in melanoma [60, 61] and small cell lung cancer [62, 63], although, to our knowledge, they have not been observed in B cell lymphoma [64, 65].